1277P - Bevacizumab in routine clinical practice for first-line therapy with platinum-based chemotherapy of patients with advanced adenocarcinoma of the lu...

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Non-Small Cell Lung Cancer
Presenter Hubert R. Wirtz
Citation Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383
Authors H.R. Wirtz1, S. Lang2, J. Mezger3, S. Hammerschmidt4, T. Gaska5, C. Lerchenmueller6, M. Reck7, S. Haas8, D. Reichert9, G. Hoeffken10
  • 1Medizinische Klinik Und Poliklinik I, Universitaetsklinikum Leipzig, 04103 - Leipzig/DE
  • 2Medizinische Klinik 2, SRH Wald-Klinikum Gera GmbH, Gera/DE
  • 3Medizinische Klinik 2, Hämatatologie, Onkologie, Immunologie, Palliativmedizin, ViDiaKliniken Karlsruhe, Karlsruhe/DE
  • 4Klinik Für Innere Medizin Iv, Klinikum Chemnitz gGmbH, Chemnitz/DE
  • 5Klinik Fuer Haematologie Und Onkologie, Bruederkrankenhaus St. Josef Paderborn, Paderborn/DE
  • 6Haematologie Und Onkologie, Ueberoertliche Gemeinschaftspraxis, Münster/DE
  • 7Department Of Thoracic Oncology, Member Of The German Center For Lung Research (dzl), LungenClinic, Airway Research Center North (ARCN), Grosshansdorf/DE
  • 8Klinik Für Haematologie, Onkologie Und Nephrologie, Friedrich-Ebert-Krankenhaus GmbH, Neumünster/DE
  • 9Oncology And Hematology, Medizinische Studiengesellschaft Nord-West GmbH, Westerstede/DE
  • 10Pneumologie, Medizinischen Klinik I des Universitätsklinikum Carl Gustav Carus, Dresden/DE



This single-arm, non-interventional study ML28306 aimed at evaluating the effectiveness and safety of 1L Bevacizumab (BEV) treatment, focusing on 4 defined age groups, with platinum-based chemotherapy in patients with unresectable advanced, metastatic or recurrent adenocarcinoma of the lung in routine practice.


The study is fully recruited with 1107 patients in 174 centers. 990 patients who received ≥1 BEV-dose to date are included in the present analysis. Enrollment started 02/2013; last patient out is expected 06/2017. Baseline characteristics, treatment regimen, effectiveness and safety data are documented for each patient. Primary endpoint is progression-free survival (PFS).


In terms of age, 34% of patients were


Effectiveness and safety data of the 2. interim analysis is in line with results of the 1. analysis and other real-world data on BEV. The mPFS of the present study is comparable to the mPFS of 6.6m of the controlled E4599 trial, while the mOS is slightly lower (12.5m vs 14.2m). The safety profile is similar across age groups. No new safety signals were observed. Elderly patients seem to benefit in the same way as younger ones.

Clinical trial identification

AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung ClinicalTrials.gov Identifier: NCT01827852

Legal entity responsible for the study

Roche Pharma AG


Roche Pharma AG


H.R. Wirtz: Membership on an advisory board or board of directors: MSD, Roche, Boehringer Ingelheim Corporate-sponsored research: TNI Medical. S. Lang, S. Hammerschmidt: Membership on an advisory board or board of directors: Roche. M. Reck: Membership on an advisory board or board of directors: Hoffmann-La Roche, Lilly, MSD, Astra Zeneca, BMS, Pfizer, Novartis, Celgene, Boehringer Ingelheim. All other authors have declared no conflicts of interest.